Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

QLGN

Qualigen Therapeutics (QLGN)

Qualigen Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:QLGN
DateTimeSourceHeadlineSymbolCompany
05/30/20244:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
05/30/20244:00PMGlobeNewswire Inc.Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting DeterminationNASDAQ:QLGNQualigen Therapeutics Inc
05/14/20244:05PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:QLGNQualigen Therapeutics Inc
05/03/20248:59PMEdgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:QLGNQualigen Therapeutics Inc
04/16/20247:00AMGlobeNewswire Inc.Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™NASDAQ:QLGNQualigen Therapeutics Inc
04/10/20248:00AMGlobeNewswire Inc.Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
04/09/20248:00AMGlobeNewswire Inc.Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual MeetingNASDAQ:QLGNQualigen Therapeutics Inc
02/27/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
02/22/20244:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
12/07/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/22/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/14/20234:30PMGlobeNewswire Inc.Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023NASDAQ:QLGNQualigen Therapeutics Inc
11/08/20232:16PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
11/07/20238:30AMGlobeNewswire Inc.Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
10/23/20238:30AMGlobeNewswire Inc.Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast CancerNASDAQ:QLGNQualigen Therapeutics Inc
10/17/20238:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
09/28/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
09/27/20238:30AMGlobeNewswire Inc.Qualigen Therapeutics Presents Scientific Data on QN-302 at AACR Special Conference: Pancreatic Cancer 2023NASDAQ:QLGNQualigen Therapeutics Inc
09/08/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:QLGNQualigen Therapeutics Inc
09/01/20234:15PMEdgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:QLGNQualigen Therapeutics Inc
08/17/20238:30AMGlobeNewswire Inc.Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
08/15/202310:04AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/15/20238:30AMGlobeNewswire Inc.Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023NASDAQ:QLGNQualigen Therapeutics Inc
08/14/20234:16PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:QLGNQualigen Therapeutics Inc
08/04/20234:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/01/20238:35AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
08/01/20238:30AMGlobeNewswire Inc.Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid TumorsNASDAQ:QLGNQualigen Therapeutics Inc
07/26/20235:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
07/24/20238:15AMGlobeNewswire Inc.Qualigen Therapeutics Divests FastPack® Diagnostics BusinessNASDAQ:QLGNQualigen Therapeutics Inc
07/13/20235:29PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:QLGNQualigen Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:QLGN

Your Recent History

Delayed Upgrade Clock